<DOC>
	<DOCNO>NCT01437423</DOCNO>
	<brief_summary>The purpose study assess safety TETRAXIM™ administer routine clinical practice accord Korea Food Drug Administration Notification No . 2009-46 `` Basic standard reexamination new drug '' base pharmaceutical law Korea .</brief_summary>
	<brief_title>Regulatory Post-Marketing Surveillance Study TETRAXIM™</brief_title>
	<detailed_description>Primary vaccination administer 2 month booster vaccination age 4 6 year .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects 2 month age ( indicate currently approve local product labeling ) give study vaccine least one dose , routine healthcare visit , primary immunization booster immunization prevention diphtheria , tetanus , pertussis , poliomyelitis . Written inform consent obtain subject 's parents/legal representative .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>TETRAXIM™</keyword>
</DOC>